Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 11.43 USD 1.42% Market Closed
Market Cap: 605.4m USD
Have any thoughts about
Stoke Therapeutics Inc?
Write Note

Intrinsic Value

STOK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one STOK stock under the Base Case scenario is 6.14 USD. Compared to the current market price of 11.43 USD, Stoke Therapeutics Inc is Overvalued by 46%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

STOK Intrinsic Value
6.14 USD
Overvaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Stoke Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for STOK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about STOK?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Stoke Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Stoke Therapeutics Inc

Provide an overview of the primary business activities
of Stoke Therapeutics Inc.

What unique competitive advantages
does Stoke Therapeutics Inc hold over its rivals?

What risks and challenges
does Stoke Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Stoke Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Stoke Therapeutics Inc.

Provide P/S
for Stoke Therapeutics Inc.

Provide P/E
for Stoke Therapeutics Inc.

Provide P/OCF
for Stoke Therapeutics Inc.

Provide P/FCFE
for Stoke Therapeutics Inc.

Provide P/B
for Stoke Therapeutics Inc.

Provide EV/S
for Stoke Therapeutics Inc.

Provide EV/GP
for Stoke Therapeutics Inc.

Provide EV/EBITDA
for Stoke Therapeutics Inc.

Provide EV/EBIT
for Stoke Therapeutics Inc.

Provide EV/OCF
for Stoke Therapeutics Inc.

Provide EV/FCFF
for Stoke Therapeutics Inc.

Provide EV/IC
for Stoke Therapeutics Inc.

Show me price targets
for Stoke Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Stoke Therapeutics Inc?

How accurate were the past Revenue estimates
for Stoke Therapeutics Inc?

What are the Net Income projections
for Stoke Therapeutics Inc?

How accurate were the past Net Income estimates
for Stoke Therapeutics Inc?

What are the EPS projections
for Stoke Therapeutics Inc?

How accurate were the past EPS estimates
for Stoke Therapeutics Inc?

What are the EBIT projections
for Stoke Therapeutics Inc?

How accurate were the past EBIT estimates
for Stoke Therapeutics Inc?

Compare the revenue forecasts
for Stoke Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Stoke Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Stoke Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Stoke Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Stoke Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Stoke Therapeutics Inc with its peers.

Analyze the financial leverage
of Stoke Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Stoke Therapeutics Inc.

Provide ROE
for Stoke Therapeutics Inc.

Provide ROA
for Stoke Therapeutics Inc.

Provide ROIC
for Stoke Therapeutics Inc.

Provide ROCE
for Stoke Therapeutics Inc.

Provide Gross Margin
for Stoke Therapeutics Inc.

Provide Operating Margin
for Stoke Therapeutics Inc.

Provide Net Margin
for Stoke Therapeutics Inc.

Provide FCF Margin
for Stoke Therapeutics Inc.

Show all solvency ratios
for Stoke Therapeutics Inc.

Provide D/E Ratio
for Stoke Therapeutics Inc.

Provide D/A Ratio
for Stoke Therapeutics Inc.

Provide Interest Coverage Ratio
for Stoke Therapeutics Inc.

Provide Altman Z-Score Ratio
for Stoke Therapeutics Inc.

Provide Quick Ratio
for Stoke Therapeutics Inc.

Provide Current Ratio
for Stoke Therapeutics Inc.

Provide Cash Ratio
for Stoke Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Stoke Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Stoke Therapeutics Inc?

What is the current Free Cash Flow
of Stoke Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Stoke Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Stoke Therapeutics Inc

Current Assets 253.6m
Cash & Short-Term Investments 239.2m
Receivables 691k
Other Current Assets 13.7m
Non-Current Assets 39.7m
Long-Term Investments 30m
PP&E 9.3m
Other Non-Current Assets 494k
Current Liabilities 49.9m
Accounts Payable 2.5m
Accrued Liabilities 15.2m
Other Current Liabilities 32.2m
Non-Current Liabilities 11.3m
Other Non-Current Liabilities 11.3m
Efficiency

Earnings Waterfall
Stoke Therapeutics Inc

Revenue
16.7m USD
Operating Expenses
-134m USD
Operating Income
-117.3m USD
Other Expenses
11.8m USD
Net Income
-105.5m USD

Free Cash Flow Analysis
Stoke Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

STOK Profitability Score
Profitability Due Diligence

Stoke Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
25/100
Profitability
Score

Stoke Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

STOK Solvency Score
Solvency Due Diligence

Stoke Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
71/100
Solvency
Score

Stoke Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 22.73 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.

Lowest
Price Target
15.15 USD
33% Upside
Average
Price Target
22.73 USD
99% Upside
Highest
Price Target
36.75 USD
222% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for STOK?

Click here to dive deeper.

Dividends

Stoke Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for STOK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

STOK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

605.1m USD

Dividend Yield

0%

Description

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Contact

MASSACHUSETTS
Bedford
3 Preston Ct
+17814308200.0
www.stoketherapeutics.com

IPO

2019-06-19

Employees

102

Officers

CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
Co-Founder & Independent Director
Dr. Adrian R. Krainer Ph.D.
Chief Medical Officer
Dr. Barry S. Ticho FACC, M.D., Ph.D.
Co-Founder & Senior VP of Discovery Research
Ms. Isabel Aznarez Ph.D.
Chief Financial Officer
Mr. Thomas Edward Leggett
Head of Investor Relations
Mr. Eric Rojas
Show More
Corporate Secretary & General Counsel
Mr. Jonathan Allan J.D.
Chief Communications Officer
Ms. Dawn Kalmar
Chief Human Resources Officer
Ms. Joan Wood
Chief Regulatory Officer
Ms. Shamim Ruff M.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one STOK stock?

The intrinsic value of one STOK stock under the Base Case scenario is 6.14 USD.

Is STOK stock undervalued or overvalued?

Compared to the current market price of 11.43 USD, Stoke Therapeutics Inc is Overvalued by 46%.

Back to Top